title: The impact of baseline left ventricular size and mitral regurgitation on reverse left ventricular remodelling in response to carvedilol: size doesn't matter.
authors.forename: E
authors.initials: E
authors.lastname: Kotlyar
authors.forename: C S
authors.initials: CS
authors.lastname: Hayward
authors.forename: A M
authors.initials: AM
authors.lastname: Keogh
authors.forename: M
authors.initials: M
authors.lastname: Feneley
authors.forename: P S
authors.initials: PS
authors.lastname: Macdonald
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000209:etiology; D000077261:Carvedilol; D002908:Chronic Disease; D004452:Echocardiography; D006801:Humans; D008944:Mitral Valve Insufficiency / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D012189:Retrospective Studies; D018487:Ventricular Dysfunction, Left / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol